These authors also provided in vivo evidence that loss of TRPC1 function impairs tumor growth in immunocompromised mice, suggesting that pharmacological inhibition of these channels may slow tumor growth (Bomben and Sontheimer, 2010). Here, TRPC1 is linked to neoplasm.